Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Eli Lilly & Company Develops Novel Antipsychotic for Treating Schizophrenia

February 27, 2008

Analysis of:Daring to Think Differently About Schizophrenia | www.nytimes.com

All currently marketed antipsychotic medications for treating schizophrenia rely on mechanisms of action which target dopamine and serotonin receptors. Although these medications reduce delusions and hallucinations without inducing symptoms of Parkinson's Disease or other abnormal muscle movements, they are not effective in relieving the cognitive impairment and social withdrawal which are the most disabling features of the illness and have other dangerous effects on weight, glucose control, cholesterol and lipids. Lilly Pharmaceutical has developed LY2140023 which acts by modulating the activity of certain receptors for glutamate, and in an early trial has demonstrated superiority to placebo in reducing delusions, hallucinations, cognitive impairment, and social withdrawal without causing neurological side effects or dangerous metabolic effects.

Page : 11 to 1 of 1

Subscribe to Updates

By RSS